Isatuximab and Pd: A Real-Life Look in Japan

In Japan, doctors kept an eye on how well isatuximab plus pomalidomide and dexamethasone (Isa-Pd) worked for people with relapsed or refractory multiple myeloma (RRMM) who were frail. They collected data from patients treated between October 2020 and October 2021, following them for up to a year. Out of the total, 40 people were frail, 29 were fit or intermediate, and 51 had no frailty score. The frail group had more side effects like bone-marrow suppression, infections, and infusion reactions compared to the fit/intermediate group.

Interestingly, heart failure only happened to one person with no frailty. The fit/intermediate group responded better to treatment, with 56% showing an overall response and 36% a very good partial response or better. However, both groups had similar rates of stopping treatment due to the disease getting worse. This study shows that Isa-Pd can be safe and effective for frail RRMM patients in real-world settings in Japan.

Actions